This article was originally published in The Gray Sheet
Executive SummarySen. Judd Gregg (R- N.H.) plans Senate HELP Committee hearings this fall to consider follow-up legislation to the Project Bioshield Act (S 15) to address, among other topics, corporate liability for products developed under the program. The legislation, approved in the House July 14 following Senate passage May 19, secures $5.6 bil. in funding over the next five years for development of diagnostic and therapeutic countermeasures against bioterrorism agents and ensures rapid regulatory review, when necessary. AdvaMed has backed the Bioshield provisions since the concept was unveiled during President Bush's 2003 State of the Union address. The association also has maintained the importance of liability protection for products used in emergency...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.